Wacker Chemie, a Munich, Germany-headquartered company, has acquired from SynCo Bio Luxembourg, a contract manufacturing organization, a Dutch site for manufacturing biopharmaceuticals, live microbial products, and vaccines, plus associated business. 

SynCo Bio Partners has approximately 110 employees and operates two fermentation lines with capacities of 1,500 and 270 liters. These lines manufacture microbial-derived biopharmaceuticals for clinical testing and the commercial market. It has a further line of single-use fermenters, which provides additional and flexible production capabilities. SynCo’s service offering also includes fill/finish manufacturing. 

The acquisition adds to the capabilities of Wacker Biotech GmbH, a contract manufacturer of bio-pharmaceutical proteins based on microbial systems. The company’s services range from molecular biology, analytical services and process development through to the GMP manufacture of clinical test samples and pharmaceutical actives for the commercial market at its German-based Jena and Halle plants.

Source: Wacker